A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. [electronic resource]
Producer: 20070613Description: 1762-8 p. digitalISSN:- 1078-0432
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Arsenic Trioxide
- Arsenicals -- administration & dosage
- Ascorbic Acid -- administration & dosage
- Boronic Acids -- administration & dosage
- Bortezomib
- Disease-Free Survival
- Female
- Humans
- Male
- Middle Aged
- Multiple Myeloma -- drug therapy
- Oxides -- administration & dosage
- Pyrazines -- administration & dosage
- Recurrence
- Survival Analysis
- Treatment Failure
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.